Section Arrow
Quote
ATHE.NASDAQ
- Alterity Therapeutics Limited
Quotes are at least 15-min delayed:2025/09/03 18:55 EDT
After Hours
Last
 5.05
-0.02 (-0.39%)
Bid
5
Ask
5.27
High 5.05 
Low 5.05 
Volume 1 
Regular Hours
Last
 5.07
-0.09 (-1.74%)
Day High 
5.16 
Prev. Close
5.16 
1-M High
5.59 
Volume 
7.18K 
Bid
5
Ask
5.27
Day Low
5 
Open
5.14 
1-M Low
4.895 
Market Cap 
76.39M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.04 
20-SMA 5.15 
50-SMA 4.84 
52-W High 7 
52-W Low 1.001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.14/-1.30
Enterprise Value
76.47M
Balance Sheet
Book Value Per Share
1.87
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PMNProMIS Neurosciences0.4574-0.0792-14.76%6.98PE
After Hours 0.4169 -0.0405 -8.85%
ADAPAdaptimmune Therapeutics plc0.0526-0.0052-9.00%-- 
After Hours 0.0536 +0.001 +1.90%
CARMCarisma Therapeutics0.3699-0.0701-15.93%-- 
After Hours 0.3515 -0.0184 -4.97%
ETHZETHZilla Corporation2.52-0.15-5.62%-- 
After Hours 2.5 -0.02 -0.79%
STTKShattuck Labs1.28+0.27+26.73%-- 
After Hours 1.27 -0.01 -0.78%
Quotes are at least 15-min delayed：2025/09/03 18:55 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.